BIODESIX INC
Summit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.
Several biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.
Biodesix (BDSX) hit a 52-week high of $29.18, up over 90% in three months. Q2 2026 revenue rose to $26.9M from $20.1M in Q2 2025, showing growth.
Over the past 7 days, alphai's AI scored 3 news stories mentioning BDSX (BIODESIX INC). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent BDSX coverage spans market movers, earnings and insider activity.
In the last 30 days, BDSX insiders filed 3 SEC Form 4 transactions — 3 purchases ($1.0M) and no sales. The most active reporter was SCHULER JACK W with 3 filings.
Robust earnings beat supports continued bullish bias.
Revenue growth supports bullish view; price may continue upward trend.
Revenue beat suggests strong demand for lung‑diagnostic tests, supporting further upside.
Earnings call data points to accelerating Nodify adoption, improving margins, and continued progress toward adjusted EBITDA profitability while reiterating full-year revenue guidance.
The filing is a fresh insider purchase signal, but it is not a fundamental catalyst like earnings or guidance.
alphai scores every news story that mentions BDSX with an AI model for sentiment and relevance, and aggregates insider trades from BIODESIX INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Summit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.
3 min readSeveral biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.
3 min readBiodesix (BDSX) hit a 52-week high of $29.18, up over 90% in three months. Q2 2026 revenue rose to $26.9M from $20.1M in Q2 2025, showing growth.
1 min readBiodesix (BDSX) reported Q2 2026 results and discussed clinical demand drivers for its Nodify lung nodule biomarkers. The company said March publication of a lung nodule validation study increased Nodify CDT orders for nodules as small as 4 mm. Q2 revenue rose 34% to $26.9M, diagnostic testing revenue $25.4M (+42%), gross margin 82%, and net loss was $7.3M. Full-year revenue outlook remains $108M to $114M.
7 min readSCHULER JACK W purchased 15,000 indirectly-held shares of BIODESIX INC (BDSX) at $24.47 ($0.37M total) on 2026-08-12.
1 min readSCHULER JACK W purchased 27,600 indirectly-held shares of BIODESIX INC (BDSX) at an average of $24.13 ($24.01–$24.25, $0.67M total) across 2 trades over 2026-08-10 to 2026-08-11.
2 min readBiotech stocks hit 52-week highs Aug. 10 on trial and earnings updates. Silence Therapeutics (SLN) rose about 29% to $17.58 after Phase 2 SANRECO topline results for divesiran and a reduced Q2 net loss, plus an announced ~$150M ADS offering. AbCellera (ABCL) gained ~34% to $10.01 on Phase 2 ABCL635 data. Cumberland (CPIX) reached $8.45 on Phase 2 Ifetroban progress. Celldex (CLDX) rose to $43.21 on Barzolvolimab Phase 3/2 readouts. Biodesix (BDSX) hit $25.51 after Q2 revenue of $26.9M and FY gui
2 min readBIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Confere
4 min readBiodesix (NASDAQ: BDSX) has filed an S-3 registration statement to allow Perceptive Credit Holdings IV, LP to resell up to 375,000 shares of common stock. These shares are issuable upon the exercise of warrants granted under multiple amendments to a credit agreement. Biodesix will not receive proceeds from the resale of these shares, but would receive proceeds if the warrants are exercised for cash.
2 min readBiodesix, Inc. (NASDAQ:BDSX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $32.50. The company reported better-than-expected quarterly earnings and revenue, and its stock has seen a recent increase of 5.1%. Insider buying has also been noted, with more shares purchased than sold in the last 90 days.
2 min read
